Movement Alert｜Akeso Inc Rises 3.03% in Regular Trading, ASCO Plenary Session Oral Presentation Approaching as Key Catalyst

Market Focus

May 27

On May 27, Akeso Inc rose 3.03% in regular trading, trading at 115.7 HKD/share, with trading volume of HKD 260 million. The stock notably outperformed most peers in the biotech sector, which traded broadly weaker on the same day.

On the news front, the ASCO Annual Meeting is set to open on May 29, and Akeso's core product ivonescimab (PD-1/VEGF bispecific antibody) HARMONi-6 study has been selected for a plenary session oral presentation, where overall survival data will be disclosed. This marks the first time a China-originated First-in-Class drug has been featured in the ASCO plenary session, generating strong market anticipation for the upcoming clinical readout.

It is worth noting that Akeso's share price has pulled back over 25% from its prior high following the disappointing HARMONi-3 global Phase III interim analysis, in which the squamous cell carcinoma cohort failed to meet the pre-specified statistical significance threshold for progression-free survival. The current rally reflects pre-event positioning ahead of the critical academic window.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/news/1112746835"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1112746835\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1112746835?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-27 11:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1112746835","market":"us","top_or_hot":-1,"title":"Movement Alert｜Akeso Inc Rises 3.03% in Regular Trading, ASCO Plenary Session Oral Presentation Approaching as Key Catalyst","media":"Market Focus","content":"<p><p>On May 27, Akeso Inc rose 3.03% in regular trading, trading at 115.7 HKD/share, with trading volume of HKD 260 million. The stock notably outperformed most peers in the biotech sector, which traded broadly weaker on the same day.</p><p>On the news front, the ASCO Annual Meeting is set to open on May 29, and Akeso's core product ivonescimab (PD-1/VEGF bispecific antibody) HARMONi-6 study has been selected for a plenary session oral presentation, where overall survival data will be disclosed. This marks the first time a China-originated First-in-Class drug has been featured in the ASCO plenary session, generating strong market anticipation for the upcoming clinical readout.</p><p>It is worth noting that Akeso's share price has pulled back over 25% from its prior high following the disappointing HARMONi-3 global Phase III interim analysis, in which the squamous cell carcinoma cohort failed to meet the pre-specified statistical significance threshold for progression-free survival. The current rally reflects pre-event positioning ahead of the critical academic window.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Akeso Inc Rises 3.03% in Regular Trading, ASCO Plenary Session Oral Presentation Approaching as Key Catalyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Akeso Inc Rises 3.03% in Regular Trading, ASCO Plenary Session Oral Presentation Approaching as Key Catalyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-05-27 11:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On May 27, Akeso Inc rose 3.03% in regular trading, trading at 115.7 HKD/share, with trading volume of HKD 260 million. The stock notably outperformed most peers in the biotech sector, which traded broadly weaker on the same day.</p><p>On the news front, the ASCO Annual Meeting is set to open on May 29, and Akeso's core product ivonescimab (PD-1/VEGF bispecific antibody) HARMONi-6 study has been selected for a plenary session oral presentation, where overall survival data will be disclosed. This marks the first time a China-originated First-in-Class drug has been featured in the ASCO plenary session, generating strong market anticipation for the upcoming clinical readout.</p><p>It is worth noting that Akeso's share price has pulled back over 25% from its prior high following the disappointing HARMONi-3 global Phase III interim analysis, in which the squamous cell carcinoma cohort failed to meet the pre-specified statistical significance threshold for progression-free survival. The current rally reflects pre-event positioning ahead of the critical academic window.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1112746835","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1112746835","pubTimestamp":1779851423,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On May 27, Akeso Inc rose 3.03% in regular trading, trading at 115.7 HKD/share, with trading volume of HKD 260 million. The stock notably outperformed most peers in the biotech sector, which traded...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"走势提示|康方生物公司常规交易上涨3.03%，ASCO全体会议口头陈述临近成为关键催化剂","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"On May 27, Akeso Inc rose 3.03% in regular trading, trading at 115.7 HKD/share, with trading volume of HKD 260 million. The stock notably outperformed most peers in the biotech sector, which traded broadly weaker on the same day.On the news front, the ASCO Annual Meeting is set to open on May 29, and Akeso's core product ivonescimab (PD-1/VEGF bispecific antibody) HARMONi-6 study has been selected for a plenary session oral presentation, where overall survival data will be disclosed. This marks the first time a China-originated First-in-Class drug has been featured in the ASCO plenary session, generating strong market anticipation for the upcoming clinical readout.It is worth noting that Akeso's share price has pulled back over 25% from its prior high following the disappointing HARMONi-3 global Phase III interim analysis, in which the squamous cell carcinoma cohort failed to meet the pre-specified statistical significance threshold for progression-free survival. The current rally reflects pre-event positioning ahead of the critical academic window.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}